Previous 10 | Next 10 |
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common...
2024-02-06 16:03:41 ET More on Gilead Sciences Gilead Sciences: The Sky Is Not Falling Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Gilead set to roll out Q4 results p...
Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for Full Year 2023 Oncology Sales Increased Year-Over-Year by 37% for Full Year 2023 Gilead Sciences, Inc. (Nasdaq: GILD) announced today its ...
NORTHAMPTON, MA / ACCESSWIRE / February 6, 2024 / We believe that innovation thrives when bright, diverse and imaginative minds come together. We're proud to offer an inclusive culture that enables all people to do their best work, and we're happy to be named one of Newsweek America's Greatest...
Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...
2024-02-06 01:10:00 ET Summary Some big tech results fizzled, but there were two standouts last week. Nine S&P 500® companies have outlier earnings dates this week - MCD, IEX, EW, MAA, MCK, HSY, COP, TROW, CTLT. 1,558 companies are expected to report during the second...
2024-02-05 19:07:19 ET More on Gilead Sciences Gilead Sciences: The Sky Is Not Falling Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Gilead Sciences stock traded in the...
2024-02-05 13:59:25 ET Gilead Sciences ( NASDAQ: GILD ) shares trade in the red for the seventh consecutive day, down 0.18% at $76.82 on Wednesday, one day before reporting its fourth quarter results. Short interest on GILD stands at 1.38% of total float.... Read the full arti...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
2024-02-04 08:45:00 ET As Wall Street embarks on the first full week of February, a large number of companies are set to release their earnings reports, providing a crucial glimpse into their financial standing and future outlook. From industry leaders like The Walt Disney Company (...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...